Diaceutics (LON:DXRX) Trading Up 9.4% – Here’s What Happened

Diaceutics PLC (LON:DXRX – Get Free Report)’s share price traded up 9.4% during trading on Tuesday . The stock traded as high as GBX 186.90 and last traded at GBX 186. 1,307,491 shares traded hands during mid-day trading, an increase of 546% from the average daily volume of 202,378 shares. The stock had previously closed at GBX 170.

Analyst Ratings Changes

Separately, Canaccord Genuity Group reissued a “buy” rating and set a GBX 215 target price on shares of Diaceutics in a research report on Tuesday. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of GBX 215.

Get Diaceutics alerts:

Get Our Latest Stock Analysis on DXRX

Diaceutics Stock Up 1.5%

The firm has a market capitalization of £164.93 million, a price-to-earnings ratio of 1,766.82 and a beta of 0.88. The company has a debt-to-equity ratio of 2.85, a current ratio of 3.43 and a quick ratio of 9.92. The business has a fifty day moving average price of GBX 146.97 and a two-hundred day moving average price of GBX 151.24.

Diaceutics (LON:DXRX – Get Free Report) last released its earnings results on Tuesday, September 22nd. The company reported GBX (3.27) EPS for the quarter. Diaceutics had a return on equity of 0.25% and a net margin of 0.25%. On average, equities analysts expect that Diaceutics PLC will post 1.0107919 earnings per share for the current year.

About Diaceutics

(Get Free Report)

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.

Further Reading

• Five stocks we like better than Diaceutics
• DraftKings Falls 7.6%: Is Kalshi’s NFL Lead Really That Big?
• Gaming Your Portfolio: Should You Add Take-Two Ahead of GTA 6’s November Launch?
• Chips to Bots: Qualcomm’s Agentic AI Breakout
• Ciena Fell 40%—Now One Analyst Sees 50% Upside

Receive News & Ratings for Diaceutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diaceutics and related companies with MarketBeat.com's FREE daily email newsletter.